Results 241 to 250 of about 50,598 (255)

T Cell Signalling Through CD73

Cellular Signalling, 1997
CD73 (ecto-5'-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.
R, Resta, L F, Thompson
openaire   +2 more sources

������������������������������������������������PD-L1���CD73������������������

2022

openaire   +1 more source

Anti‐CD73 therapy impairs tumor angiogenesis

International Journal of Cancer, 2013
CD73 is an ecto‐nucleotidase overexpressed in various types of tumors that catabolizes the generation of extracellular adenosine, a potent immunosuppressor. We and others have shown that targeted blockade of CD73 can rescue anti‐tumor T cells from the immunosuppressive effects of extracellular adenosine.
Bertrand, Allard, Martin, Turcotte, Kathleen, Spring, Sandra, Pommey, Isabelle, Royal, John, Stagg   +5 more
openaire   +2 more sources

CD73 Inhibitors as Antitumor Agents

2023
5′-Ectonucleotidase (e5NT), a metalloenzyme incorporating two zinc ions in its structure, also known as CD73, hydrolyzes AMP to phosphate and adenosine. It is involved in several physiological and pathological processes, among which immune homeostasis, inflammation, tumor progression. The last decade saw the development of small molecule and monoclonal
Capasso, Clemente, Nocentini, Alessio, Supuran, Claudiu T.   +2 more
openaire   +2 more sources

CD73 (5′-Ectonucleotidase)

5′-Ectonucleotidase (e5NT), a metalloenzyme also known as CD73, hydrolyzes AMP to phosphate and adenosine. In mammalians, CD73 is involved in several physiological and pathological processes, among which immune homeostasis, inflammation, and tumor progression.
Supuran C. T., Capasso C.
openaire   +2 more sources

Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis

Clinical & Experimental Metastasis, 2013
Angiogenesis is essential for tumor growth, progression and metastasis. Studies indicate that expression and activity of ecto-5'-nucleotidase (CD73) are elevated in metastatic carcinomas. Our previous studies found that angiogenesis of tumor xenografts was decreased when the activity of CD73 in cancer cells was inhibited, implying that this enzyme is ...
Li, Wang, Shaoxian, Tang, Yingjian, Wang, Siguang, Xu, Jerry, Yu, Xiuling, Zhi, Zhouluo, Ou, Jiayin, Yang, Ping, Zhou, Zhimin, Shao   +9 more
openaire   +2 more sources

RETRACTED: Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib

Life Sciences, 2020
Conventional therapeutic methods against cancer, including chemotherapy, radiotherapy, surgery, and combination therapy, have exhibited different toxicity levels due to their unspecific mechanism of action. To overcome the challenges facing conventional cancer therapies, newly developed methods are being investigated. Significant levels of specificity,
Shahin, Hallaj, Sima, Heydarzadeh Asl, Fatemeh, Alian, Sajjad, Farshid, Farzaneh Sadat, Eshaghi, Afshin, Namdar, Fatemeh, Atyabi, Ali, Masjedi, Tooba, Hallaj, Anahita, Ghorbani, Ghasem, Ghalamfarsa, Mozhdeh, Sojoodi, Farhad, Jadidi-Niaragh   +12 more
openaire   +2 more sources

Evaluation of CD73 in lung cancer.

Journal of Clinical Oncology, 2017
e14525 Background: Immunotherapy has shown promising results in multiple forms of cancer including lung cancer patients. Treatment targeting alternative immune checkpoints may demonstrate value for specific cancers or in combination therapy with other immunotherapies or chemotherapeutic agents.
Hui Yu, Maya Amar, Christopher J Rivard, Kim Ellison, Leslie Rozeboom, Kenichi Suda, Kristine Brovsky, Fred R. Hirsch   +7 more
openaire   +1 more source

Novel CD73 Inhibitors for Treating Cancer

ACS Medicinal Chemistry Letters
Provided herein are novel CD73 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
openaire   +2 more sources

Bispecific antibodies targeting human CD73

2017
The present invention relates to a bispecific antibody targeting CD73. In particular, the present invention relates to a bispecific antibody targeting different epitopes on CD73 or a bispecific antibody targeting an epitope on CD73 and an epitope on a different antigen.
Ditzel, Henrik, Gammelgaard, Odd Lilleng
openaire   +1 more source